I would expect that COGS wouldn’t be an issue as Betadine is sold over the counter and in supermarkets. So I think the model would work however if it is just the Australian market then sales will be cyclic to the cold season.
I think what Avecho are doing is a little bit different with their Phase 3 to get TGA backed over the counter packaged CBD for insomnia. There it makes sense as an alternative to prescription medication and minimal over the counter options.
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
7.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $15.72M | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 8500 | 6.7¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 6.9¢ | 5000 | 1 |
View Market Depth
| Last trade - 07.10am 25/06/2025 (20 minute delay) ? |
| FRE (ASX) Chart |
Day chart unavailable